Li Dianbo, Gong Liping
Department of Thoracic Surgery, Linyi Tumor Hospital, Linyi, Shandong, People's Republic of China.
Drug Des Devel Ther. 2016 Sep 6;10:2815-2821. doi: 10.2147/DDDT.S113670. eCollection 2016.
The aim of this study was to develop and characterize pirfenidone (PF)-loaded chitosan microspheres for lung targeting. The microspheres were prepared using the emulsion-solvent evaporation method and characterized by assessing morphology, particle size, and zeta potential. The microspheres had a spherical nature with highly smooth and integrated surfaces. The particle size of microspheres was 4.6±0.3 µm, and the zeta potential was 20.3±1.4 mV. The in vitro release results indicated that the obtained formulation of PF could reach the state of sustained release with a biphasic drug release pattern. It was observed that there was no significant difference in both the percentage of entrapment efficiency and that of drug release before and after the stability study. In vivo, the calculated relative bioavailability indicated greater pulmonary absorption of PF when it was encapsulated in microspheres. According to histopathological studies, no histological change occurred to the rat lung after the administration of PF-loaded chitosan microspheres.
本研究的目的是开发并表征用于肺部靶向的载有吡非尼酮(PF)的壳聚糖微球。采用乳化溶剂蒸发法制备微球,并通过评估形态、粒径和zeta电位对其进行表征。微球呈球形,表面高度光滑且完整。微球的粒径为4.6±0.3 µm,zeta电位为20.3±1.4 mV。体外释放结果表明,所获得的PF制剂能够达到缓释状态,呈现双相药物释放模式。观察到稳定性研究前后的包封率和药物释放率均无显著差异。在体内,计算得出的相对生物利用度表明,PF包封于微球中时肺部吸收更佳。根据组织病理学研究,给予载有PF的壳聚糖微球后,大鼠肺部未发生组织学变化。